Ziopharm Oncology Company Profile (NASDAQ:ZIOP)

Analyst Ratings

Consensus Ratings for Ziopharm Oncology (NASDAQ:ZIOP) (?)
Ratings Breakdown: 1 Sell Rating(s), 3 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $10.83 (124.76% upside)

Analysts' Ratings History for Ziopharm Oncology (NASDAQ:ZIOP)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016MizuhoReiterated RatingNeutral$7.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2016Wells Fargo & Co.Reiterated RatingUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2016Griffin SecuritiesReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/15/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2015BMO Capital MarketsDowngradeOutperform -> Market Perform$15.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2015GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Ziopharm Oncology (NASDAQ:ZIOP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.08)($0.09)$1.89 million$1.97 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2016Q4($0.07)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2015Q315($0.13)($0.14)$1.19 million$1.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.22)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.13)($0.10)$0.20 million$0.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q414($0.14)($0.09)$420.00 million$0.34 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314($0.12)($0.06)$3.43 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.17)($0.06)$7.50 million$0.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.10)($0.10)$0.20 million$0.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2014Q413($0.15)($0.09)$0.20 million$0.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2013Q313($0.17)($0.20)$0.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.24)($0.22)$0.20 million$0.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2013Q4 2012($0.29)($0.48)$0.17 million$0.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.28)($0.28)$0.20 million$0.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.23)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.22)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2012($0.23)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011($0.28)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2011($0.23)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ziopharm Oncology (NASDAQ:ZIOP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.07)($0.07)($0.07)
Q2 20161($0.12)($0.12)($0.12)
Q3 20161($0.12)($0.12)($0.12)
Q4 20161($0.13)($0.13)($0.13)
Q2 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ziopharm Oncology (NASDAQ:ZIOP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ziopharm Oncology (NASDAQ:ZIOP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/4/2015Murray BrennanDirectorSell40,000$9.70$388,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015Randal J KirkDirectorBuy1,440,000$8.75$12,600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2013Randal J KirkDirectorBuy2,857,143$3.50$10,000,000.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ziopharm Oncology (NASDAQ:ZIOP)
DateHeadline
07/29/16 10:32 AM2 Biotech Stocks News And Price Trends: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Progenics Pharmaceuticals, Inc ... - The Voice Registrar
07/29/16 10:32 AMEarnings Analysis to see: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), IAC/InterActiveCorp (NASDAQ:IAC) - News Oracle
07/28/16 07:56 PMBiotech news that matter for investors: Nektar Therapeutics ... - The Voice Registrar
07/28/16 07:56 PMNotable Stocks within Analysts Radar: Johnson & Johnson (NYSE ... - Street Updates
07/28/16 07:56 PMNotable Research Reports: Jabil Circuit, Inc. (NYSE:JBL), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) - Review Fortune
07/26/16 11:01 AMInvestigation for Investors in Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) over Potential Violations of Securities Laws
07/25/16 07:38 PMWells Fargo & Company (NYSE:WFC) went up 0.04%: Intrexon Corporation (NYSE:XON), ZIOPHARM Oncology, Inc ... - KC Register
07/22/16 07:13 PMAnalysts Reviewing Stocks Update: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , ZIOPHARM Oncology Inc ... - Street Updates
07/22/16 07:13 PM2 Biotech Stocks News And Price Trends: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Opko Health, Inc. (NASDAQ:OPK) - The Voice Registrar
07/22/16 07:13 PMZIOPHARM Oncology Inc (ZIOP) Drops 8.02% on July 19 - Equities.com
07/22/16 07:13 PMZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Earns Consensus Hold Rating - Review Fortune
07/22/16 07:13 PMHC Stocks Alerts: Skyline Medical Inc (NASDAQ:SKLN), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) - share market updates (press release)
07/22/16 10:22 AMBiotech industry kills another cancer patient in experimental drug study
07/21/16 07:47 PMZIOPHARM Oncology : Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
07/21/16 10:16 AMZIOPHARM shares higher after update on brain cancer study
07/20/16 10:25 AMSHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of ZIOPHARM Oncology, Inc. and Reminds Investors with Losses to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that it is investigating claims against ZIOPHARM Oncology, Inc. concerning possible violations of federal securities laws.
07/20/16 10:20 AMZIOPHARM Oncology shares higher as it updates on brain cancer study
07/20/16 10:20 AMShares of ZIOPHARM Oncology Inc (ZIOP) Drops by -17.05%
07/20/16 07:35 AMBRIEF-ZIOPHARM has no plans to access capital markets in securities offering - * ZIOPHARM Oncology Inc says currently has no plans to access capital markets in a securities offering
07/19/16 07:38 PMEquity Roundup: Stock Performance Focus on ZIOPHARM Oncology Inc (NASDAQ:ZIOP) - Press Telegraph
07/19/16 07:38 PMStock Falling to a Recent Low: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) - Press Telegraph
07/19/16 07:38 PMTrading the Biotech News: Exelixis, Inc. (NASDAQ:EXEL), ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) - The Voice Registrar
07/19/16 08:22 AMIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of ZIOPHARM Oncology, Inc. and Advises Investors with Losses to Contact the Firm
07/19/16 08:22 AMZIOPHARM ONCOLOGY INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
07/19/16 08:22 AMZiopharm Oncology (ZIOP) Updates on Ad-RTS-hIL-12 Phase 1 in r/p GBM; Says One Death Deemed Unrelated to Study, Will Report to FDA (XON)
07/19/16 07:01 AMZIOPHARM ONCOLOGY INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
07/17/16 06:48 PMZiopharm Oncology (ZIOP) Issues Statement on Ad-RTS-hIL-12 Phase 1 in GBM; Believes Prelim. Overall Survival 'Encouraging'
07/17/16 06:48 PMFederman & Sherwood : Investigates ZIOPHARM Oncology, Inc. for Possible Violations of Federal Securities Laws
07/17/16 04:12 AMShares Moving Down on the Week: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) - Engelwood Daily
07/16/16 06:42 PMShares Experiencing a Downtrend: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) - TGP
07/16/16 10:35 AMCrowd Rating and Earnings Recap for ZIOPHARM Oncology Inc (NASDAQ:ZIOP) - Telanagana Press
07/16/16 10:35 AMIncreased Volatility Noted on Shares of: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) - Engelwood Daily
07/16/16 10:35 AMBRIEF-Ziopharm Oncology updates on early study for brain cancer drug - Reuters
07/16/16 10:35 AMFederman & Sherwood Investigates ZIOPHARM Oncology, Inc. for Possible Violations of Federal Securities Laws - Business Wire (press release)
07/15/16 07:16 PMIMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against ZIOPHARM Oncology, Inc. And Advises Investors With Losses To Contact The Firm - [Business Wire] - Goldberg Law PC announces that it is investigating claims against ZIOPHARM Oncology, Inc. concerning possible violations of federal securities laws.
07/15/16 06:26 PMBronstein, Gewirtz & Grossman, LLC Announces Investigation of ZIOPHARM Oncology, Inc — SHAREHOLDER ALERT
07/15/16 06:26 PMHow Some ZIOP Buyers Got Screwed On Thursday Night
07/15/16 06:26 PMFederman & Sherwood Investigates ZIOPHARM Oncology, Inc. for Possible Violations of Federal Securities Laws
07/15/16 06:26 PMZiopharm Oncology Reports Patient’s Death
07/15/16 12:47 PMZIOPHARM Oncology (ZIOP) Slumps on Negative Tweet
07/15/16 12:47 PMBuzz Stocks: Wells Fargo & Co, Herbalife Ltd., and ZIOPHARM Oncology Inc.
07/15/16 12:47 PMZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
07/15/16 12:47 PMShareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ZIOPHARM Oncology, Inc. - ZIOP
07/15/16 12:47 PMZiopharm Plunges After Patient Dies in Brain Cancer Study (1)
07/15/16 12:47 PMCancer patient dies after Ziopharm experimental drug therapy
07/15/16 12:44 PMWhy ZIOP Shorts Got Screwed On Thursday Night - Shares of ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) sold off hard Thursday night after The Street's Adam Feuerstein tweeted that a brain cancer patient had died after receiving an injection of the company's gene therapy drug. But some traders looking to take advantage of the news with a quick short were unable to place their orders due to the uptick rule. PreMarket Prep co-host Dennis Dick ranted about it on Friday's show. What's The Uptick Rule? The uptick rule was reinstated in 2010 by the SEC. According to the rule, stocks are only allowed to be shorted on upticks in price. Essentially, it limits the ability for short sellers to short a stock by preventing traders from shorting when the most recent trade is lower. What Happened Last Night? In order to short, the most recent trade must be higher. This can create a backlog of people trying to get short a stock when it's trading down. This was on display Thursday night with Ziopharm. Dick explained: "If you look the previous day, Ziopharm went from $6.04 to $5.39, so it fell 10 percent. That means [during] yesterday's trade you could not hit the bid to get short. So [ZIOP] comes out with bad news. The stock wants to go down, but you cannot short it to get down. So savvy traders ...Full story available on Benzinga.com
07/14/16 07:41 PMWatch These 7 Huge Call Purchases In Thursday Trade - Benzinga
07/14/16 07:41 PMWells Fargo Weighs In on Ziopharm Oncology Inc (ZIOP) Following Initiation of Phase 1 Trial in AML - Smarter Analyst
07/13/16 10:16 AMStock Update (NASDAQ:ZIOP): ZIOPHARM Oncology Inc. Announces Plans for Phase I Clinical Trial with CD33 CAR-T ... - Smarter Analyst
07/13/16 10:16 AMShort Term Rating on ZIOPHARM Oncology Inc (ZIOP) - TheFounders Daily

Social

About Ziopharm Oncology

Ziopharm Oncology logoZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company's Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ZIOP
  • CUSIP: 98973P10
Key Metrics:
  • Previous Close: $4.82
  • 50 Day Moving Average: $5.61
  • 200 Day Moving Average: $6.79
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $626.34M
  • Beta: 1.61
  • Current Year EPS Consensus Estimate: $-0.41 EPS
  • Next Year EPS Consensus Estimate: $-0.46 EPS
Additional Links:
Ziopharm Oncology (NASDAQ:ZIOP) Chart for Friday, July, 29, 2016